About MGBase

What is the MGBase Registry?

The first global observational registry to be launched for patients diagnosed with Myasthenia Gravis.

Patient registries such as MGBase are powerful instruments for expanding our knowledge of diseases. They are particularly useful in rare diseases, such as MG, where they can provide the opportunity to pool ‘real world’ data to reach a sufficient sample size for epidemiological and clinical research.

The MGBase Registry is the first global observational registry to be launched for patients diagnosed with Myasthenia Gravis. Developed as an extension to the highly successful MSBase Registry for patient with Multiple Sclerosis, the MGBase registry is dedicated to evaluating outcomes data in Myasthenia Gravis through collaborative international research. As a global MG database, MGBase will significantly advance myasthenia research and improve the quality of care and outcomes for patients with MG.

MGBase is designed to be used in an outpatient clinic during regular neurological consultations. It provides a longitudinal graphical display of the patient disease course, therapies and outcomes. It is simple to input data in the clinic via an electronic Data Entry System, with de-identified data accessible to researchers. Outcome measures include symptom severity scales (eg Myasthenia Gravis Composite (MGC)), quality of life measures (eg MGQoL15R), patient reported outcome measures (eg MGII) and employment status.

The MGBase Registry is owned and operated by the MSBase Foundation Ltd, a not-for-profit company registered in Australia. The Foundation is governed by a Global Board of Directors that advises and supports the work of the registry. The MGBase Scientific Leadership Group (SLG) advises the Foundation on the scientific direction of the Registry. The Operations Team are responsible for the maintenance and management of the Registry and are centralised in Melbourne, Australia.